Dr. Marlena Fejzo Advocates for Maternal Health at Conference

Dr. Marlena Fejzo Advocates for Women's Health Research

Dr. Marlena Fejzo, an accomplished geneticist and Research Director at the HER Foundation, made a powerful impact speaking at the inaugural White House Conference on Women's Health Research. Her presence at this significant conference underscores the pressing need for increased focus on maternal health, particularly regarding hyperemesis gravidarum (HG).

Championing Maternal Health

For over two decades, Dr. Fejzo has dedicated her life to studying hyperemesis gravidarum, a rare but severely debilitating condition during pregnancy. Despite the challenges, including minimal institutional funding, she has made groundbreaking discoveries, such as identifying GDF15 as the primary cause of nausea and vomiting in pregnancy. Currently, her efforts are directed towards developing effective treatments and prevention strategies for HG.

A Personal Journey

During her presentation, Dr. Fejzo shared her personal story, recounting her tragic experience with HG in 1999, which resulted in the loss of her pregnancy. "Hyperemesis gravidarum was ten unbearable weeks of constant suffering, devastating for me and my family, and fatal for my innocent, unborn child," she shared. She expressed her frustration at how often women's suffering is minimized, as she was once told she was exaggerating her symptoms.

Upon recovery, Dr. Fejzo was shocked by the lack of scientific research into HG, and that realization propelled her to devote her career to understanding the condition.

Understanding Hyperemesis Gravidarum

Hyperemesis gravidarum is the most severe form of nausea and vomiting during pregnancy, affecting nearly up to 10% of pregnant women globally. This condition poses serious risks, including preterm birth and fetal loss, impacting up to 34% of cases. The financial implications are staggering, with hospital costs linked to HG exceeding $3 billion annually in the United States alone.

The Challenge of HG

Dr. Fejzo emphasized that while morning sickness may lead to an average of 23 missed workdays, those suffering from HG can miss around 60 days. "This condition is far beyond mere morning sickness; it can be a life-altering and life-threatening condition," she stated.

Furthermore, research suggests that babies born after an HG pregnancy may face long-term developmental challenges, potentially increasing risks for neurodevelopmental issues, speech delays, and emotional or behavioral disorders.

The Role of the HER Foundation

The HER Foundation has been a pivotal entity in the global effort to raise awareness, conduct research, and advocate for hyperemesis gravidarum since its founding in 2000. Executive Director Kimber MacGibbon stressed the importance of funding for HG research, stating, "These often-preventable challenges can affect families financially and emotionally throughout their lives. It's time we devoted resources to HG research."

About Hyperemesis Gravidarum

• Hyperemesis gravidarum affects over 6 million mothers worldwide on an annual basis.
• This condition is the leading cause of hospitalization during early pregnancy.
• Risks associated with HG include premature delivery and placental disorders.
• Children born from HG pregnancies face increased risks of developmental and behavioral disorders.

The HER Foundation's Commitment

The HER Foundation continues to lead initiatives that reshape the understanding of hyperemesis gravidarum through innovative research and community support. With a mission focused on finding a cure and improving access to effective care, the foundation aims to enhance outcomes for mothers and their babies.

Dr. Fejzo and HER's contributions have provided essential resources for management and support, including treatment protocols and the HG Care iOS app, to assist families facing this challenging condition.

Frequently Asked Questions

What is hyperemesis gravidarum?

Hyperemesis gravidarum is the most severe form of nausea and vomiting during pregnancy, affecting approximately 10% of pregnant women and leading to significant health risks.

Who is Dr. Marlena Fejzo?

Dr. Marlena Fejzo is the Research Director at the HER Foundation and a renowned geneticist recognized for her work in advancing understanding and research around hyperemesis gravidarum.

What are the risks associated with hyperemesis gravidarum?

Risks include fetal loss, preterm birth, and developmental challenges for children born after an HG pregnancy.

How does the HER Foundation contribute to HG awareness?

The HER Foundation leads research, education, and advocacy efforts to improve understanding and treatment of hyperemesis gravidarum.

Why is funding for HG research important?

Funding is crucial to advance research that could lead to better treatment and prevention of HG, ultimately improving health outcomes for affected families.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.